NNC0487-0111

also known as NNC0487-0111 A

Developed for: obesity disorder · type 2 diabetes mellitus · obstructive sleep apnea syndrome · osteoarthritis, knee · heart failure
Investigated by: Novo Nordisk A/S

Trials 19 · a red edge is where a trial was stopped

today NCT07400107 · Ph 3 NCT07587710 · Ph 1 NCT07567001 · Ph 3 NCT07571005 · Ph 3 NCT07571109 · Ph 3 NCT07503210 · Ph 3 NCT07509307 · Ph 3 NCT07481630 · Ph 3 NCT07533175 · Ph 3 NCT07535307 · Ph 1 NCT07508020 · Ph 1 NCT07339423 · Ph 3 NCT07121153 · Ph 1 NCT06820476 · Ph 1 NCT06559527 · Ph 1 NCT06542874 · Ph 2 NCT06461039 · Ph 1 NCT06064006 · Ph 2 NCT06049329 · Ph 1

202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 18 trials
Phase 1	NCT07587710	May 2026 → Dec 2027 expected	obesity disorder	Novo Nordisk A/S	Not yet recruiting	No outcome recorded
Phase 1	NCT07535307	Apr 2026 → Nov 2027 expected	type 2 diabetes mellitus	Novo Nordisk A/S	Recruiting	No outcome recorded
Phase 1	NCT07508020	Mar 2026 → Jan 2028 expected	obesity disorder	Novo Nordisk A/S	Recruiting	No outcome recorded
Phase 1	NCT07121153	Aug → Dec 2025	obesity disorder	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT06820476	Feb → May 2025	obesity disorder	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT06559527	Aug 2024 → Feb 2025	obesity disorder, type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT06461039	Jun 2024 → Mar 2025	obesity disorder	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT06049329	Sep → Dec 2023	obesity disorder	Novo Nordisk A/S	Completed	No outcome recorded
Phase 22 trials
Phase 2	NCT06542874	Aug 2024 → Oct 2025	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 2	NCT06064006	Sep 2023 → Nov 2024	obesity disorder	Novo Nordisk A/S	Completed	No outcome recorded
Phase 39 trials
Phase 3	NCT07400107	May 2026 → Dec 2028 expected	obesity disorder, type 2 diabetes mellitus	Novo Nordisk A/S	Not yet recruiting	No outcome recorded
Phase 3	NCT07567001	May 2026 → Jul 2029 expected	heart failure, obesity disorder	Novo Nordisk A/S	Recruiting	No outcome recorded
Phase 3	NCT07571005	May 2026 → Jul 2028 expected	obesity disorder, obstructive sleep apnea syndrome	Novo Nordisk A/S	Recruiting	No outcome recorded
Phase 3	NCT07571109	May 2026 → Jun 2028 expected	obesity disorder, obstructive sleep apnea syndrome	Novo Nordisk A/S	Recruiting	No outcome recorded
Phase 3	NCT07503210	Apr 2026 → Jun 2028 expected	obesity disorder	Novo Nordisk A/S	Recruiting	No outcome recorded
Phase 3	NCT07509307	Apr 2026 → Aug 2028 expected	obesity disorder, osteoarthritis, knee	Novo Nordisk A/S	Recruiting	No outcome recorded
Phase 3	NCT07481630	Apr 2026 → Aug 2028 expected	obesity disorder, osteoarthritis, knee	Novo Nordisk A/S	Recruiting	No outcome recorded
Phase 3	NCT07533175	Apr 2026 → Aug 2028 expected	obesity disorder, type 2 diabetes mellitus	Novo Nordisk A/S	Recruiting	No outcome recorded
Phase 3	NCT07339423	Feb 2026 → Jun 2029 expected	obesity disorder	Novo Nordisk A/S	Recruiting	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT06478563 Comparator	Jun 2024 → Jun 2025	obesity disorder	Novo Nordisk A/S	Completed	No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 21 sources stand behind the page.

Field	Value	Cited text
Known as	NNC0487-0111	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06461039 ↗ 19 NCT07587710 ↗ NCT07571005 ↗ NCT07571109 ↗ NCT06559527 ↗ NCT07535307 ↗ NCT06542874 ↗ NCT06820476 ↗ NCT07533175 ↗ NCT06049329 ↗ NCT06478563 ↗ NCT07400107 ↗ NCT07121153 ↗ NCT07339423 ↗ NCT07508020 ↗ NCT07503210 ↗ NCT07481630 ↗ NCT07509307 ↗ NCT07567001 ↗ NCT06064006 ↗
Known as	NNC0487-0111 A	“NNC0487-0111 A will be administered subcutaneously.” NCT06461039 ↗
Action	Activate	“glucagon-like peptide-1 and amylin receptor agonist” PMID 42443140 ↗ Jul 2026
Route	Oral	“when given as an oral tablet” NCT06049329 ↗